VU testing vaccine against new flu threat

Vanderbilt’s Vaccine and Treatment Evaluation Unit (VTEU) is one of nine U.S. sites funded by the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), to test the effectiveness of a vaccine to protect against the H7N9 bird flu that emerged in China this spring.

Hyundai award helps drive hope for cancer research

Emmanuel Volanakis, M.D., assistant professor of Pediatrics and Hematology/Oncology, was awarded a $250,000 Hyundai Hope On Wheels grant last week for his ongoing research into T-cell acute lymphoblastic leukemia (ALL), an aggressive blood cancer.

VU tracking drug’s ability to prevent type 1 diabetes

Vanderbilt’s Eskind Diabetes Clinic has been selected to examine the ability of the drug abatacept to prevent type 1 diabetes (T1D). As part of the TrialNet consortium, Vanderbilt will be one of 14 North American sites observing the effects of the drug in people at high risk to develop T1D.

Options to treat childhood C. diff. infection studied

After more than a month in and out of the hospital with her daughter, Kynslee, Kristen Allen felt she was at the end of her rope. Last spring, the nearly 2-year-old Columbia girl developed diarrhea that wouldn’t go away after taking antibiotics for repeated ear infections.

‘Proofreader’ key to coronavirus growth

A coronavirus protein is required for replication of the viral genome and may be a good treatment target for SARS and other diseases caused by coronaviruses.

Webber delivers first State of Pediatrics address